Lilly Cuts Arzoxifene Losses, Will Not File NDA

After initial results from a five-year, Phase III trial showed the drug fell short on key secondary outcome measures, Lilly has decided not to file the application with FDA.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet